Healthcare
Sol-Gel Technologies Ltd.(SLGL)
Live Price
Offline$73.44
-2.47% today
1Y Change
+917.32%
Window
Jun 20, 2025 โ Jun 12, 2026
- Market Cap
- $210.00M
- Revenue Growth
- +68.0%
- EPS Growth
- -478.9%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 20, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sol-Gel Technologies Ltd. (SLGL) is a Healthcare stock with a market cap of $210.00M and listed on NASDAQ. The stock last traded around $73.44 and up 917.3% across the available one-year price window (Jun 20, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +68.0%, EPS growth of -478.9%, a dividend yield of 0.0%. What stands out right now is revenue +68.0%, EPS -478.9%, free cash flow +102.0% with operating margin 54.4% and ROIC 43.5%. Valuation already assumes a fairly strong business story at price/sales 11.0. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines SLGL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+68.0% vs +7.6% peer median
Operating Margin
Above sector median
+54.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 22, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +68.0% and EPS is at -478.9%, with operating margin around 54.4%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.8% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 22, 2026 | โ | -2.9% | -8.2% | โ |
2026 Mar 19, 2026 | -374.4% | -10.7% | -4.8% | -9.6% |
2025 Nov 20, 2025 | -1.9% | +2.5% | +18.6% | +17.9% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SLGL
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SLGL Max Drawdown
-35.38%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SLGL and SPY.
Company Overview
Sol-Gel Technologies Ltd.
NASDAQ Global Market
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
- Leadership
- Moshe Arkin
- IPO Date
- Feb 1, 2018
- Employees
- 34
- Street Address
- 7 Golda Meir Street
- Mailing
- Ness Ziona, 7403650
- Region
- Ness Ziona, IL
- Reporting Currency
- USD
- Investor Line
- 972 8 931 3433
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 18.6
- Price/Sales
- 11.0
- Price/Book
- 9.2
Growth
- Revenue
- +68.0%
- EPS
- -478.9%
- Free Cash Flow
- +102.0%
Profitability
- Gross Margin
- 100.0%
- Operating Margin
- 54.4%
- Net Margin
- -31.6%
- ROE
- -24.3%
- ROIC
- 43.5%
Balance Sheet
- Debt/Equity
- 0.04
- Current Ratio
- 4.37
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.